

**Huntley Pharmaceuticals Limited**  
**Annual Report and Financial Statements**  
Registered number 05081628  
Year ended 31 March 2018

WEDNESDAY



LD2 \*L7K5ØQZK\* #21  
05/12/2018  
COMPANIES HOUSE

## Company information

<b>Company registration number</b>	05081628
<b>Registered office</b>	Suite 1, Third Floor, 11-12 St James Square London SW1Y 4LB
<b>Directors</b>	B Patel V Patel A Patel D Patel M Cotterill
<b>Auditor</b>	KPMG LLP Botanic House, 100 Hills Road Cambridge CB2 1AR
<b>Secretaries</b>	Jordan Company Secretaries Limited First Floor, Templeback Temple Back Bristol BS1 6FL

## Contents

Directors' report	1
Statement of directors' responsibilities in respect of the directors' report and the financial statements	2
Independent auditor's report to the members of Huntley Pharmaceuticals Limited	3
Profit and loss account	5
Balance sheet	6
Notes	7

## Director's report

The directors present their report together with the financial statements for the year ended 31 March 2018.

### Principal activity and review of the business

The principle activity of the Company is to hold the trademark for a pharmaceutical product.

The results for the year are set out on page 5.

The directors do not recommend the payment of a dividend (2017: £nil).

### Directors

The directors of the Company during the year and since the year end were:

V Patel  
D Patel  
B Patel  
A Patel  
M Cotterill

The Company did not provide qualifying third party indemnity provisions to its directors during the year (2017: nil).

### Disclosure of information to auditor

The directors who held office at the date of approval of this directors' report confirm that, so far as they are each aware, there is no relevant audit information of which the Company's auditor is unaware; and each director has taken all the steps that he/she ought to have taken as a director to make himself/herself aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

### Auditor

Pursuant to Section 487 of the Companies Act 2006, the auditor will be deemed to be reappointed and KPMG LLP will therefore continue in office.

By order of the board



**B Patel**  
Director

Date: 30 July 2018

11-12 St James Square  
London  
United Kingdom  
SW1Y 4LB

## **Statement of directors' responsibilities in respect of the directors' report and the financial statements**

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with applicable law and Section 1A of FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (UK Generally Accepted Accounting Practice applicable to Smaller Entities).

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent; and
- assess the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.



## **Independent auditor's report to the members of Huntley Pharmaceuticals Limited**

### **Opinion**

We have audited the financial statements of Huntley Pharmaceuticals Limited ("the company") for the year ended 31 March 2018, which comprise the profit and loss account, balance sheet and related notes, including the accounting policies in note 1.

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2018 and of its profit for the year then ended;
- have been properly prepared in accordance with UK accounting standards applicable to smaller entities, including Section 1A of FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland*; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities are described below. We have fulfilled our ethical responsibilities under, and are independent of the company in accordance with, UK ethical requirements including the FRC Ethical Standard, and the provisions available for small entities, in the circumstances set out in note 1 to the financial statements. We believe that the audit evidence we have obtained is a sufficient and appropriate basis for our opinion.

### **Going concern**

We are required to report to you if we have concluded that the use of the going concern basis of accounting is inappropriate or there is an undisclosed material uncertainty that may cast significant doubt over the use of that basis for a period of at least twelve months from the date of approval of the financial statements. We have nothing to report in these respects.

### **Directors' report**

The directors are responsible for the directors' report. Our opinion on the financial statements does not cover that report and we do not express an audit opinion thereon.

Our responsibility is to read the directors' report and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work:

- we have not identified material misstatements in the directors' report;
- in our opinion the information given in that report for the financial year is consistent with the financial statements; and
- in our opinion that report has been prepared in accordance with the Companies Act 2006.

## **Independent auditor's report to the members of Huntley Pharmaceuticals Limited** *(continued)*

### **Matters on which we are required to report by exception**

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption from the requirement to prepare a strategic report.

We have nothing to report these respects.

### **Directors' responsibilities**

As explained more fully in their statement set out on page 2, the directors are responsible for: the preparation of the financial statements and for being satisfied that they give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

### **Auditor's responsibilities**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue our opinion in an auditor's report. Reasonable assurance is a high level of assurance, but does not guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

A fuller description of our responsibilities is provided on the FRC's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities).

### **The purpose of our audit work and to whom we owe our responsibilities**

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

**Mark Prince (Senior Statutory Auditor)**  
**for and on behalf of KPMG LLP, Statutory Auditor**  
*Chartered Accountants*  
Botanic House  
100 Hills Road  
Cambridge CB2 1AR  
United Kingdom  
30 July 2018

**Profit and loss account**  
*for the year ended 31 March 2018*

	<i>Note</i>	<b>2018</b> £	<b>2017</b> £
Turnover	2	519,525	498,184
Cost of sales		(2,020)	(10,855)
<b>Gross profit</b>		<b>517,505</b>	<b>487,329</b>
Administrative expenses		(892)	(9,243)
<b>Operating profit</b>		<b>516,613</b>	<b>478,086</b>
Interest payable and similar expense		(87)	(182)
<b>Profit on ordinary activities before taxation</b>		<b>516,526</b>	<b>477,904</b>
Tax on profit on ordinary activities	5	(98,140)	(95,507)
<b>Profit for the financial year</b>		<b>418,386</b>	<b>382,397</b>

All amounts relate to continuing activities.

There were no other components of comprehensive income during 2018 or 2017. As a result, total comprehensive income for the year is the same as the profit for the year.

The notes on pages 7 to 11 form part of these financial statements.




**Balance sheet**  
*at 31 March 2018*

	Note	2018 £	2017 £
<b>Current assets</b>			
Debtors	6	2,709,526	2,098,921
Cash at bank and in hand		4,825	103,856
		<u>2,714,351</u>	<u>2,202,777</u>
<b>Creditors: amounts falling due within one year</b>	7	<u>(182,964)</u>	<u>(89,776)</u>
<b>Net current assets</b>		<u>2,531,387</u>	<u>2,113,001</u>
<b>Total assets less current liabilities</b>		<u>2,531,387</u>	<u>2,113,001</u>
<b>Net assets</b>		<u>2,531,387</u>	<u>2,113,001</u>
<b>Capital and reserves</b>			
Called up share capital	8	40,000	40,000
Profit and loss account		2,491,387	2,073,001
<b>Equity shareholders' funds</b>	9	<u>2,531,387</u>	<u>2,113,001</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS102 Section 1A – small entities.

The notes on pages 7 to 11 form part of these financial statements.

These financial statements were approved and signed by the directors on 30 July 2018.

  
**B C Patel**  
Director

Registered number: 05081628

## Notes

*(Forming part of the financial statements)*

### 1 Accounting policies

#### *Basis of preparation*

The Company is a private company limited by shares and incorporated in England and Wales. The address of its registered office is: 11-12 St James Square, London, SW1Y 4LB. The principal place of business is Sovereign House, Miles Gray Road, Basildon, SS14 3FR.

These financial statements are prepared in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland ("FRS102") Section 1A Small Entities as issued in September 2015. The presentation currency of these financial statements is sterling.

The accounting policies set out below have, unless otherwise stated been applied consistently to all period presented in these financial statements. On the first time adoption of FRS102 Section 1A Small Entities, the Company has not retrospectively changed its accounting under old UK GAAP for de-recognition of financial assets and liabilities before the date of transition, accounting estimates or discontinued operations.

In these financial statements, the Company has applied the exemptions available under FRS102 Section 1A Small Entities in respect of the following disclosures:

- a Cash Flow Statement and related notes;
- a Statement of Changes in Equity;
- disclosures in respect of transactions with wholly owned subsidiaries.

The consolidated financial statements of Atnahs Pharma UK Limited, within which the Company is included, can be obtained from the address given in Note 11.

The financial statements are prepared under the historical cost convention and in accordance with applicable accounting standards.

#### *Going concern*

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis.

#### *Current Tax*

Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the profit and loss account except to the extent that it relates to items recognised directly in equity or other comprehensive income, in which case it is recognised directly in equity or other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided on timing differences which arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the financial statements. The following timing differences are not provided for: differences between accumulated depreciation and tax allowances for the cost of a fixed asset if and when all conditions for retaining the tax allowances have been met; and differences relating to investments in subsidiaries, [associates, branch, joint ventures] to the extent that it is not probable that they will reverse in the foreseeable future and the reporting entity is able to control the reversal of the timing difference. Deferred tax is not recognised on permanent differences arising because certain types of income or expense are non-taxable or are disallowable for tax or because certain tax charges or allowances are greater or smaller than the corresponding income or expense.

Deferred tax is measured at the tax rate that is expected to apply to the reversal of the related difference, using tax rates enacted or substantively enacted at the balance sheet date. Deferred tax balances are not discounted.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

## Notes (continued)

### 1 Accounting policies (continued)

#### Foreign currencies

Transactions denominated in foreign currencies are recorded in the local currency at actual exchange rates as at the date of transaction.

Monetary assets and liabilities denominated in foreign currency at the year-end are reported at the rates of exchange prevailing at the year end. Any gain or loss arising from a change in exchange rates is included in the profit and loss account.

#### Turnover

Turnover represents the amounts (excluding value added tax) derived from the provision of services during the period.

### 2 Turnover

Turnover relates to the royalty due from the out-licencing of the trademark held by the Company.

### 3 Auditor's remuneration

	2018	2017
	£	£
Audit of these financial statements	1,000	1,000

Auditor's remuneration costs for services provided to the Company were borne entirely by Atnahs Pharma UK Limited, the immediate parent company.

### 4 Staff costs and directors' remuneration

There were no employees in the current year or in the previous year and therefore no staff costs (2017: £nil).

The directors are also directors of Atnahs Pharma UK Limited, the immediate parent company. During the period the directors received emoluments through Atnahs Pharma UK Limited, but it is not practicable to allocate this between their services as directors of Atnahs Pharma UK Limited and other companies within the group. The directors' work is spread across the companies and it can be expected that typically within any given period between 0-5 per cent of their time would be allocated to the Company. Details of emoluments received by the directors for their services to the group are disclosed in the accounts of Atnahs Pharma UK Limited.

**Notes (continued)**

**5 Taxation**

*Total tax expense recognised in the profit and loss account, other comprehensive income and equity*

	2018 £	2017 £
<i>Current tax</i>		
Current tax on income for the year	98,140	95,581
Adjustments in respect of prior periods	-	(74)
Total current tax	98,140	95,507
Total tax	98,140	95,507

*Factors affecting current tax charge for the year*

A reduction in the UK corporation tax rate from 20% to 19% (effective from 1 April 2017) and to 18% (effective 1 April 2020) were substantively enacted on 26 October 2015, and an additional reduction to 17% (effective 1 April 2020) was substantively enacted on 6 September 2016. This will reduce the company's future current tax charge accordingly.

**Reconciliation of effective tax rate**

The current tax charge for the year is equal to (2017: *lower than*) the average standard rate of corporation tax for the year in the UK of 19% (2017: 20%). The explanation is below:

	2018 £	2017 £
Profit for the year excluding taxation	516,526	477,904
Tax using the UK corporation tax rate of 19% (2017: 20%)	98,140	95,581
<i>Effects of:</i>		
Adjustment to tax charge in respect of the previous periods	-	(74)
Total tax expense included in profit or loss	98,140	95,507

**Notes (continued)**

**6 Debtors**

	2018 £	2017 £
Amounts owed by group undertakings	2,709,243	2,098,184
Other debtors	283	737
	<u>2,709,526</u>	<u>2,098,921</u>

The amounts owed by group undertakings are owed by the immediate parent company, Atnahs Pharma UK Limited, and other fellow subsidiaries.

**7 Creditors: amounts falling due within one year**

	2018 £	2017 £
Trade creditors	493	5,445
Amounts owed to group undertakings	84,331	-
Corporation tax	98,140	84,331
	<u>182,964</u>	<u>89,776</u>

**8 Share capital**

	2018 £	2017 £
On issue at 1 April 2017 and 31 March 2018 – fully paid		40,000
		<u>40,000</u>
<b>Allotted, called up and fully paid</b>		
40,000 ordinary shares of £1 each	40,000	40,000
	<u>40,000</u>	<u>40,000</u>

## Notes (continued)

### 9 Reconciliation of movement in shareholders' funds

	2018 £	2017 £
Shareholders' funds at beginning of year	2,113,001	1,730,604
Profit for the year	418,386	382,397
	<hr/>	<hr/>
Shareholders' funds at end of year	2,531,387	2,113,001
	<hr/>	<hr/>

### 10 Related party disclosures

The Company has taken advantage of the exemption available under FRS102 Section 1A Small Entities, which exempts entities from the requirement to disclose related party transactions with wholly owned group companies. There were no other related party transactions in the year (2017: nil).

### 11 Ultimate controlling party

The immediate parent company is Atnahs Pharma UK Limited, a company incorporated in the UK. The ultimate controlling party is Mr V. C. Patel.

The smallest group in which the results of the Company are consolidated is that headed by Atnahs Pharma UK Limited, the immediate parent company. The consolidated financial statements of this group are available to the public and may be obtained from 11-12 St James Square, London, UK, SW1Y 4LB.